Li Meng-Shi, Li Yang, Liu Yang, Zhou Xu-Jie, Zhang Hong
Renal Division, Peking University First Hospital, Beijing, China.
Kidney Genetics Center, Peking University Institute of Nephrology, Beijing, China.
Front Med (Lausanne). 2022 May 6;9:905007. doi: 10.3389/fmed.2022.905007. eCollection 2022.
More than 200 cases of lipoprotein glomerulopathy (LPG) have been reported since it was first discovered 30 years ago. Although relatively rare, LPG is clinically an important cause of nephrotic syndrome and end-stage renal disease. Mutations in the gene are the leading cause of LPG. mutations are an important determinant of lipid profiles and cardiovascular health in the population and can precipitate dysbetalipoproteinemia and glomerulopathy. Apolipoprotein E-related glomerular disorders include 2 homozygote glomerulopathy and LPG with heterozygous mutations. In recent years, there has been a rapid increase in the number of LPG case reports and some progress in research into the mechanism and animal models of LPG. We consequently need to update recent epidemiological studies and the molecular mechanisms of LPG. This endeavor may help us not only to diagnose and treat LPG in a more personized manner but also to better understand the potential relationship between lipids and the kidney.
自30年前首次发现脂蛋白肾小球病（LPG）以来，已报告了200多例病例。尽管LPG相对罕见，但在临床上它是肾病综合征和终末期肾病的重要病因。该基因的突变是LPG的主要病因。突变是人群中脂质谱和心血管健康的重要决定因素，可引发异常β脂蛋白血症和肾小球病。载脂蛋白E相关的肾小球疾病包括2型纯合子肾小球病和伴有杂合子突变的LPG。近年来，LPG病例报告数量迅速增加，在LPG的发病机制和动物模型研究方面也取得了一些进展。因此，我们需要更新LPG的最新流行病学研究和分子机制。这一努力不仅可能帮助我们以更个性化的方式诊断和治疗LPG，还能帮助我们更好地理解脂质与肾脏之间的潜在关系。
